Video Interview: Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.

NEW YORK, June 16, 2009 (GLOBE NEWSWIRE) -- Veteran business journalist Sasha
Salama joins Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.
(PBI) to discuss the company's industry, strategy, financials and positioning.

Click here to view video:
http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=37288&k=0320DEF
9617776E555AC615ABB444D7

Mr. Richard T. Schumacher, the founder of our Company, has served as a director
of Pressure BioSciences since the formation of its legacy business, Boston
Biomedica, Inc., in 1978. He has served as CEO of Pressure BioSciences since
April 2004 and President since September 2004. He previously served as CEO and
Chairman of the Board of Boston Biomedica from 1992 to February 2003 and as
President from 1986 to August 1999. Mr. Schumacher served as the Director of
Infectious Disease Services for Clinical Sciences Laboratory, a New
England-based medical reference laboratory, from 1986 to 1988. From 1972 to
1985, Mr. Schumacher was employed by the Center for Blood Research, a nonprofit
medical research institute associated with Harvard Medical School. Mr.
Schumacher received a BS in Zoology from the University of New Hampshire.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the
development of a novel, enabling technology called Pressure Cycling Technology
(PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high
levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI
currently holds 13 US and 6 foreign patents covering multiple applications of
PCT in the life sciences field, including genomic and proteomic sample
preparation, pathogen inactivation, the control of chemical (primarily
enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently
focuses its efforts on the development and sale of PCT-enhanced enzymatic
digestion products designed specifically for the mass spectrometry marketplace,
as well as sample preparation products for biomarker discovery, soil and plant
biology, forensics, histology, and counter-bioterror applications.

The NASDAQ CEO Signature Series logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4839

For more information about NASDAQ CEO Signature Series interviews, call
978/461-3141